{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T00:36:52Z","timestamp":1787618212623,"version":"build-2736575974"},"reference-count":26,"publisher":"Wiley","issue":"19","license":[{"start":{"date-parts":[[2013,7,18]],"date-time":"2013-07-18T00:00:00Z","timestamp":1374105600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2013,10]]},"abstract":"<jats:sec><jats:title>BACKGROUND<\/jats:title><jats:p>Preoperative chemotherapy improves the outcome in patients with colorectal cancer with liver metastases. In the current study, the authors evaluated the activity of a conversion treatment with the combination of capecitabine plus oxaliplatin (XELOX) used in association with panitumumab in patients with unresectable, liver\u2010only, metastatic colon cancer.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS<\/jats:title><jats:p>Chemotherapy\u2010naive patients with unresectable liver metastases from colon cancer with no other metastatic disease sites were enrolled. All patients received upfront therapy with XELOX plus panitumumab (P\u2010XELOX) and were reevaluated for resectability every 4 cycles. The primary endpoint was the objective response rate (ORR). Secondary endpoints were overall survival (OS), progression\u2010free survival, the percentage of patients whose disease became radically resectable, and the safety of the P\u2010XELOX combination.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>A total of 49 patients were recruited, 35 of whom had wild\u2010type KRAS (wtKRAS) and 14 of whom (who were enrolled before study amendment) had unknown (9 patients) or mutated (5 patients) KRAS mutational status. Forty\u2010six patients were evaluable for response. After conversion P\u2010XELOX therapy, the ORR in the general population was 54%, with 2 complete responses, 23 partial responses, and 14 cases of stable disease. In patients with wtKRAS, the ORR of the patients reached 65% (2 CRs and 19 PRs), which allowed 15 patients with initial unresectable liver metastasis to be reclassified as having resectable disease. Survival analysis demonstrated a median progression\u2010free survival of 8.5 months and a median OS of 21.9 months. Patients who underwent surgery were found to have a significantly better OS when compared with those who did not undergo surgery (<jats:italic>P<\/jats:italic>\u2009&lt;\u2009.001). Overall, toxicities were found to be predictable and manageable, with the most common being cutaneous, gastrointestinal, and neurologic toxicities.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS<\/jats:title><jats:p>Conversion P\u2010XELOX therapy yields high response and resectability rates for patients with metastatic colon cancer with extensive liver involvement. <jats:bold><jats:italic>Cancer<\/jats:italic> 2013;119:3429\u20133435.<\/jats:bold>. \u00a9 2013 American Cancer Society.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.28223","type":"journal-article","created":{"date-parts":[[2013,7,19]],"date-time":"2013-07-19T05:03:04Z","timestamp":1374210184000},"page":"3429-3435","source":"Crossref","is-referenced-by-count":23,"title":["Panitumumab in combination with infusional oxaliplatin and oral capecitabine for conversion therapy in patients with colon cancer and advanced liver metastases"],"prefix":"10.1002","volume":"119","author":[{"given":"Francesco","family":"Leone","sequence":"first","affiliation":[{"name":"Department of Medical Oncology Piemonte Oncology Foundation, IRCC\u2010Candiolo Candiolo Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Artale","sequence":"additional","affiliation":[{"name":"Department of Oncology, Surgery, and Transplant Niguarda Ca' Granda Hospital Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donatella","family":"Marino","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Piemonte Oncology Foundation, IRCC\u2010Candiolo Candiolo Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celeste","family":"Cagnazzo","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Piemonte Oncology Foundation, IRCC\u2010Candiolo Candiolo Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Cascinu","sequence":"additional","affiliation":[{"name":"Medical Oncology Services Riuniti Umberto I University Medical Center Ancona Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmine","family":"Pinto","sequence":"additional","affiliation":[{"name":"UOC Medical Oncology Services, Azienda University Medical Center S.Orsola\u2010Malpighi Hospital Bologna Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Fornarini","sequence":"additional","affiliation":[{"name":"Medical Oncology Surgery Unit A.O. U. San Martino Hospital Genoa Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Tampellini","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology San Luigi Gonzaga Hospital Orbassano Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Di Fabio","sequence":"additional","affiliation":[{"name":"UOC Medical Oncology Services, Azienda University Medical Center S.Orsola\u2010Malpighi Hospital Bologna Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Sartore\u2010Bianchi","sequence":"additional","affiliation":[{"name":"Department of Oncology, Surgery, and Transplant Niguarda Ca' Granda Hospital Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciano","family":"De Carlis","sequence":"additional","affiliation":[{"name":"Department of Oncology, Surgery, and Transplant Niguarda Ca' Granda Hospital Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaele","family":"Pugliese","sequence":"additional","affiliation":[{"name":"Department of Oncology, Surgery, and Transplant Niguarda Ca' Granda Hospital Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Capussotti","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary and Digestive Surgery Mauriziano Hospital Torino Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luisa","family":"Gioeni","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Piemonte Oncology Foundation, IRCC\u2010Candiolo Candiolo Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Siena","sequence":"additional","affiliation":[{"name":"Department of Oncology, Surgery, and Transplant Niguarda Ca' Granda Hospital Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Aglietta","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Piemonte Oncology Foundation, IRCC\u2010Candiolo Candiolo Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,7,18]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.3322\/canjclin.55.2.74"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.05.113"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)03085-2"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.08.058"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa032691"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa033025"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(99)00150-1"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1097\/00000658-199909000-00004"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-011-2186-1"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.sla.0000141198.92114.f6"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.0928"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq714"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdi246"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.10.8126"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.13.2183"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2003.09.098"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.14.7116"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.721"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(09)70330-4"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6605940"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0805019"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.27.4860"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.27.6055"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.08.1620"},{"key":"e_1_2_7_26_1","doi-asserted-by":"crossref","first-page":"3570","DOI":"10.1200\/jco.2010.28.15_suppl.3570","article-title":"Cetuximab plus FOLFIRI: final data from the CRYSTAL study on the association of KRAS and BRAF biomarker status with treatment outcome [abstract]","volume":"28","author":"Cutsem E","year":"2010","journal-title":"J Clin Oncol"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.20.5278"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.28223","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.28223","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T10:48:00Z","timestamp":1760266080000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.28223"}},"subtitle":["The MetaPan study"],"short-title":[],"issued":{"date-parts":[[2013,7,18]]},"references-count":26,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2013,10]]}},"alternative-id":["10.1002\/cncr.28223"],"URL":"https:\/\/doi.org\/10.1002\/cncr.28223","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,7,18]]}}}